Clinicopathological features for epithelioid glioblastoma:A newly defined tumor by the 2016 World Health Organization Classification of Tumors of the Central Nervous System / 中南大学学报(医学版)
Journal of Central South University(Medical Sciences)
; (12): 398-402, 2018.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-693829
Responsible library:
WPRO
ABSTRACT
Objective:
To retrospectively summarize the clinicopathological features of epithelioid glioblastoma (Ep-GBM) and to explore new treatment for Ep-GBM.Methods:
The clinical data of 13 patients with Ep-GBM,who were treated in our department from March 2016 to July 2017,were retrospectively analyzed.The clinicopathological features were summarized and the efficacy was evaluated.Results:
The positive rate of BRAFV600E mutant and INI-1 was 76.9% (10/13) and 80% (8/10),respectively,while the median Ki-67 index was 30%.Meningeal metastases occurred in 9 cases (69.7%) during the course.The median follow-up time was 12 (6-25) months,and the median progression-free time was 8.6 (2.2-16.5) months.Three patients died and the 1-year overall survival rate was 54%.Conclusion:
Ep-GBM has a high degree of malignancy and is prone to spread to leptomeninges.INI-1 expression and BRAFV600E mutation are common for Ep-GBM.BRAF inhibitor might be a potential therapeutic drug for it.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.8 Achieve universal access to health
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Central South University(Medical Sciences)
Year:
2018
Document type:
Article